Cidara Therapeutics (CDTX) 10-Q 21 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	18-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	CIDARA THERAPEUTICS, INC.
Entity Central Index Key	1610618
Current Fiscal Year End Date	-19
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		13,510,946

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$58,124,000	$22,796,000
Prepaid expenses and other current assets	278,000	217,000
Total current assets	58,402,000	23,013,000
Property and equipment, net	814,000	863,000
Other assets	1,567,000	474,000
Total assets	60,783,000	24,350,000
Current liabilities:
Accounts payable	1,696,000	1,177,000
Accrued liabilities	1,740,000	1,622,000
Accrued compensation and benefits	373,000	414,000
Total current liabilities	3,809,000	3,213,000
Other long-term liabilities	31,000	34,000
Total liabilities	3,840,000	3,247,000
Commitments and contingencies
Stockholders' deficit:
Common stock, $0.0001 par value; 275,000,000 and 185,000,000 shares authorized at March 31, 2015 and December 31, 2014, respectively; 1,542,155 and 1,147,068 shares issued and outstanding, respectively, at March 31, 2015; 1,494,506 and 1,132,738 shares issued and outstanding, respectively, at December 31, 2014	3,000	3,000
Additional paid-in capital	2,512,000	1,856,000
Accumulated deficit	-20,041,000	-13,304,000
Total stockholders' deficit	-17,526,000	-11,445,000
Total liabilities, convertible preferred stock, and stockholders' deficit	60,783,000	24,350,000
Series A Convertible Preferred Stock
Convertible preferred stock
Convertible preferred stock	32,548,000	32,548,000
Series B Convertible Preferred Stock
Convertible preferred stock
Convertible preferred stock	$41,921,000

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Common stock, par value	$0.00	0.0001
Common stock, shares authorized	275,000,000	185,000,000
Common stock, shares issued	1,542,155	1,494,506
Common stock, shares outstanding	1,147,068	1,132,738
Series A Convertible Preferred Stock
Convertible preferred stock, par value	$0.00	0.0001
Convertible preferred stock, shares authorized	97,972,510	127,214,000
Convertible preferred stock, shares issued	97,526,081	97,526,081
Convertible preferred stock, shares outstanding	97,526,081	97,526,081
Liquidation preference	$32,769
Series B Convertible Preferred Stock
Convertible preferred stock, par value	$0.00
Convertible preferred stock, shares authorized	94,600,000	0
Convertible preferred stock, shares issued	94,533,183	0
Convertible preferred stock, shares outstanding	94,533,183	0
Liquidation preference	$42,020

Condensed_Statements_of_Operat

Condensed Statements of Operations (unaudited) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Operating expenses:
Research and development	$4,935	$278
General and administrative	1,797	281
Total operating expenses	6,732	559
Loss from operations	-6,732	-559
Other expense:
Interest expense, net	-5	-45
Change in fair value of convertible notes payable		-103
Total other expense	-5	-148
Net loss	($6,737)	($707)
Net loss per common share, basic and diluted	($5.92)	($1.81)
Weighted average shares outstanding used to compute net loss per share, basic and diluted	1,138,911	389,839

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Operating activities:
Net loss	($6,737)	($707)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	91
Stock-based compensation	639	2
Non-cash interest expense		35
Change in fair value of convertible notes payable		103
Amortization of debt issue costs	6	10
Changes in assets and liabilities:
Prepaid expenses and other current assets	-44	-24
Accounts payable and accrued liabilities	34	156
Accrued compensation	-41	15
Net cash used in operating activities	-6,052	-410
Investing activities:
Purchases of property and equipment	-31	-1
Net cash used in investing activities	-31	-1
Financing activities:
Proceeds from sales of Series B convertible preferred stock, net of issuance costs	41,921
Proceeds from exercise of stock options	116	10
Deferred initial public offering costs	-626
Proceeds from issuance of convertible notes payable, net of issuance costs		930
Net cash provided by financing activities	41,411	940
Net increase in cash and cash equivalents	35,328	529
Cash and cash equivalents at beginning of period	22,796	185
Cash and cash equivalents at end of period	58,124	714
Non-cash investing activity:
Property and equipment acquired but not yet paid	22
Non-cash financing activities:
Deferred initial public offering costs incurred but not yet paid	$490

The_Company_and_Basis_of_Prese

The Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
The Company and Basis of Presentation	1. THE COMPANY AND BASIS OF PRESENTATION
	Description of Business
	Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives. The Company’s initial product portfolio is comprised of proprietary product candidates for the treatment of serious fungal infections.
	Initial Public Offering
	On April 20, 2015, the Company completed its initial public offering (“IPO”) whereby the Company sold 4,800,000 shares of common stock at a price of $16.00 per share.  Proceeds from the IPO were approximately $69.4 million, net of underwriting discounts and commissions and offering costs.  In connection with the IPO, the outstanding shares of the Company’s Series A convertible preferred stock (“Series A preferred”) and Series B convertible preferred stock (“Series B preferred”) automatically converted into 7,561,380 shares of common stock.
	Basis of Presentation
	The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced net losses and negative cash flows from operating activities since its inception. At March 31, 2015, the Company had an accumulated deficit of $20.0 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. The Company plans to continue to fund its losses from operations and capital funding needs through debt and equity financing or through collaborations or partnerships with other companies. Debt or equity financing may not be available on a timely basis on terms acceptable to the Company, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects.
	Use of Estimates—The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company’s financial statements relate to estimating the fair value of the Company’s common shares used to account for share-based compensation, accounting for certain accruals and the fair value of the Company’s convertible notes payable. Although the estimates are based on the Company’s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
	Segment Information—Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Comprehensive Loss—Net loss and comprehensive loss were the same for all periods presented; therefore, a separate statement of comprehensive loss is not included in the accompanying financial statements.
	Cash and Cash Equivalents—The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents. At times, the Company has cash and cash equivalents deposited at financial institutions in excess of federally insured deposit limits. However, cash is held on deposit in major financial institutions and is considered subject to minimal credit risk. Cash and cash equivalents are readily available in checking and money market accounts.
	Fair Value of Financial Instruments—Financial instruments including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate their fair value based on the short maturities of those instruments.
	Concentration of Credit Risk—The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. Periodically, the Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.
	Deferred Initial Public Offering Costs—As of March 31, 2015, the Company had capitalized approximately $1.5 million of costs directly associated with the Company’s IPO. The Company will offset deferred IPO costs against IPO proceeds upon the consummation of the offering. Deferred IPO costs are included as a component of other long-term assets on the balance sheet.
	Patent Costs—The legal and professional costs incurred by the Company to acquire patent rights have been recorded as general and administrative expense since recoverability of such expenditures is uncertain.
	Convertible Preferred Stock—The Company’s Series A preferred and Series B preferred are classified as temporary equity instead of stockholders’ deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities, as the stock is conditionally redeemable at the holder’s option and upon certain change in control events that are outside the Company’s control, including the liquidation, sale, or transfer of control of the Company. Upon such change in control events, holders of the convertible preferred stock can cause its redemption.
	Income Taxes—The Company follows the FASB Accounting Standards Codification, or ASC, 740 Income Taxes, or ASC 740, in reporting deferred income taxes. The ASC 740 requires a company to recognize deferred tax liabilities and assets for expected future income tax consequences of events that have been recognized in the Company’s financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.
	Research and Development Costs—To date, research and development expenses have related primarily to research and preclinical development of CD101 IV, CD101 topical, and the Cloudbreak immunotherapy platform. Research and development expenses include compensation and benefits for research and development employees, and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.
	Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.
	Stock-based Compensation—Stock-based compensation expense represents the cost of the grant date fair value of employee stock option and restricted stock grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. The Company accounts for stock options granted to non-employees using the fair value approach. These option grants are subject to periodic revaluation over their vesting terms. The Company estimates the fair value of employee and non-employee stock option grants using the Black-Scholes option pricing model, or Black-Scholes.
	Net Loss Per Share—Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, convertible notes payable, unvested restricted common stock subject to repurchase, and options outstanding under the Company’s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.
	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):
		Three months ended
		March 31,
		2015		2014
	Convertible preferred stock		7,561,380		-
	Common stock options		1,416,779		-
	Common stock subject to repurchase		395,087		56,822
	Total		9,373,246		56,822
	Fair Value of Financial Instruments—The Company follows authoritative guidance with respect to fair value reporting issued by the FASB for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.
	Recently Issued Accounting Standards—The Company has evaluated the recent accounting pronouncements through the date of this filing, and management does not expect adoption of such pronouncements to have a material impact on the Company’s financial statements.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. FAIR VALUE MEASUREMENTS
	The Company follows ASC 820-10, Fair Value Measurements and Disclosures, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.
	As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
	Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;
	Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumption, which reflect those that a market participant would use.
	At March 31, 2015 and December 31, 2014, the Company held securities of a money market fund which invests in short-term U.S. Treasury securities, the prices of which are available from quoted prices in active markets. The carrying amounts of the Company’s financial instruments, including accounts payable, and accrued liabilities, approximate fair value due to their short maturities.
	None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.
	The following tables summarize the Company’s financial instruments measured at fair value on a recurring basis:
				LEVEL 1		LEVEL 2		LEVEL 3
		TOTAL		QUOTED		SIGNIFICANT		SIGNIFNCANT
				PRICES IN		OTHER		UNOBSERVABLE
				ACTIVE		OBSERVABLE		INPUTS
				MARKETS		INPUTS
				FOR IDENTICAL
				SECURITIES
	31-Dec-14
	Assets:
	Money market funds, included in cash and cash equivalents	$	20,769	$	20,769	$	-	$	-
	Total assets at fair value	$	20,769	$	20,769	$	-	$	-
	31-Mar-15
	Assets:
	Money market funds, included in cash and cash equivalents	$	56,372	$	56,372	$	-	$	-
	Total assets at fair value	$	56,372	$	56,372	$	-	$	-

Debt

Debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt	4. DEBT
	2013 Convertible Notes Payable
	During 2013, the Company issued convertible notes (the 2013 Notes) to a major shareholder of the Company, 5AM Ventures, for an aggregate of $1,250,000. The 2013 Notes bore interest at 8% which compounded annually. The 2013 Notes were convertible into preferred shares of the Company’s equity securities at a 15% discount to the sales price of the equity securities sold at the next financing or a series of related transactions yielding gross proceeds to the Company of at least $13,750,000 (defined as a Qualified Financing). The 2013 Notes were to mature on the earlier of a Qualified Financing, a change in control, or February 8, 2014, or such later date as provided for by the written consent of the note holders. In January 2014, the holders of the 2013 Notes executed a written consent to extend the maturity date of the 2013 Notes to July 30, 2014.
	2014 Convertible Notes Payable
	In January and February 2014, the Company issued convertible notes (the 2014 Notes) to 5AM Ventures and certain non-affiliated investors for $500,000 and $450,000, respectively. The 2014 Notes bore interest at 8%, which compounded annually. The 2014 Notes were convertible into preferred shares of the Company’s equity securities at a 15% discount to the sales price of the equity securities sold in a Qualified Financing. The 2014 Notes were to mature on the earlier of a Qualified Financing, a change in control, or July 30, 2014, or such later date as provided for by the written consent of the note holders
	On May 30, 2014, the outstanding principal balance of both the 2013 Notes and the 2014 Notes plus all accrued interest thereon converted into 321,492 shares of Series A preferred.
	Comerica Loan
	In December 2014, the Company entered into a Loan and Security Agreement with Comerica Bank, or the Comerica Loan, to borrow up to $10 million. The Comerica Loan is secured by substantially all of the Company’s assets other than intellectual property (except rights to payment from the sale, licensing, or disposition of such intellectual property). The Comerica Loan may be drawn upon by the Company through December 2015. The Comerica Loan bears interest at either Comerica’s Prime Reference Rate or LIBOR plus Comerica’s LIBOR Spread Rate, as defined in the Comerica Loan. The terms allow for a 12-month interest-only period and all outstanding term loans under the credit facility will begin amortizing at the end of the interest-only period, with monthly payments of principal and interest to be made in 36 consecutive installments following the interest-only period. Any advances made on the Comerica Loan would become due in December 2018. The Company has the right to repay any borrowings on the Comerica Loan in full without prepayment penalty. The Company issued a warrant for the purchase of Series A preferred equal to 1.5% of the total borrowings under the Comerica Loan divided by the warrant purchase price of $8.5344 per share. If advances are made on the Comerica Loan, the warrant will become exercisable on the earlier to occur of (1) the date on which the aggregate amount of advances under the Comerica Loan equals $10 million or (2) December 29, 2015. If no advances are made on the Comerica Loan by December 29, 2015, the warrant will terminate. As of March 31, 2015, the Company has not drawn any advances on the Comerica Loan.  The Company incurred $22,000 in costs associated with the execution of the Comerica Loan.  During the three months ended March 31, 2015, $6,000 of debt issue costs were amortized and recognized as interest expense in the statement of operations.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' Equity	5. STOCKHOLDERS’ EQUITY
	Convertible Preferred Stock—As of March 31, 2015, the Company had authorized 97,972,510 shares of Series A preferred and 94,600,000 shares of Series B preferred.
	In February 2015, the Company issued 94,533,183 shares of Series B preferred stock resulting in $42.0 million in gross proceeds.  The original issue price of Series B preferred was $0.4445 (the Series B Original Issue Price) which was subject to adjustment in the event of certain corporate events, such as stock dividends, combinations, splits, or recapitalizations.
	The key terms of the Series A preferred and Series B preferred (collectively, Preferred) are as follows:
	Conversion: Each share of Preferred is optionally convertible at any time at the discretion of the holder. All shares of Preferred are convertible upon the election of the holders of at least 60% of the Preferred. The number of shares of common stock into which the Preferred convert (the Preferred Conversion Rate) is calculated by dividing the Original Issue Price by the applicable Conversion Price, which is initially equal to the Original Issue Price but will be adjusted for any splits, combinations, stock dividends or distributions, reclassifications, exchanges, substitutions, reorganizations, mergers or consolidations. Additionally, subject to customary exceptions, if the Company issues additional securities at an effective price below the current applicable Conversion Price, the applicable Conversion Price will be adjusted pursuant to a broad-based antidilution calculation. In the event of an IPO at an effective price per common share greater than three times the Original Issue Price, the Preferred will automatically convert into common stock, and all declared and unpaid dividends on the Series A preferred shall be paid.
	Dividends: The Preferred has a dividend preference that is equal to 8% of the Original Issue Price. Dividends will be paid only on declaration by the board of directors and shall be non-cumulative. If dividends are paid on shares of common stock, the holders of Preferred will receive an additional dividend equal to the amount paid or set aside for each share of common stock, on an as-if-converted to common stock basis.
	Liquidation: Upon the liquidation, dissolution, or winding up of the company, each holder of Series A convertible preferred stock shall receive a preferential payment from the assets available for distribution equal to the Original Issue Price and any outstanding and declared and unpaid dividends. After the full preference amount is paid, each holder of Preferred shall receive, for each share of Preferred, an additional payment equal to the amount paid for each share of common stock until the Preferred shareholders have received a total distribution amount equal to three times the applicable Original Issue Price, plus any declared and unpaid dividends. An asset transfer or acquisition of the Company shall be treated as a liquidation.

Stock_Incentive_Plan

Stock Incentive Plan	3 Months Ended
	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Incentive Plan	6. STOCK INCENTIVE PLAN
	2013 Equity Incentive Plan
	The 2013 Option and Grant Plan, or the 2013 Plan, provides for granting stock options and restricted stock awards to certain employees, directors and consultants of the Company.
	Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2013 Plan. Stock options granted by the Company typically vest over a four year period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to ten years from the date of grant. The exercise price for stock options granted under the 2013 Plan must be at a price no less than 100% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price shall be no less than 110% of the estimated value on the date of grant. As of March 31, 2015 and December 31, 2014, the Company had 2,064,624 shares and 1,126,813 shares, respectively, authorized for issuance to employees, nonemployee directors, and consultants of the Company under the 2013 Plan.
	At March 31, 2015, there remained 194,564 shares available for future grants or awards under the 2013 Plan.
	2015 Equity Incentive Plan
	In March 2015, the Company’s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan (“2015 Plan”).  The 2015 Plan became effective on April 14, 2015, the date of execution and delivery of the underwriting agreement for the Company’s IPO.  Under the 2015 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other wards to individuals who are then employees, officers, directors, or consultants of the Company.  A total of 1,634,456 shares of common stock were approved to be reserved for issuance under the 2015 Plan.  The shares reserved exclude shares of common stock reserved for issuance under the 2013 Plan.  The number of shares reserved that are remaining under the 2013 Plan will be added to the shares initially reserved under the 2015 Plan upon its effectiveness.  In addition, the number of shares of stock available for issuance under the 2015 Plan will be automatically increased each January 1, beginning on January 1, 2016, by 4% of the outstanding number of shares of the Company’s common stock on the immediately preceding December 31 or such lesser number as determined by the Company’s board of directors.
	Employee Stock Purchase Plan
	In March 2015, the Company’s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan (“ESPP”).  The ESPP became effective on April 14, 2015.  A total of 245,168 shares of common stock were approved to be initially reserved for issuance under the ESPP.  In addition, the number of shares of stock available for issuance under the ESPP will be automatically increased each January 1, beginning on January 1, 2016, by the lesser of (i) 1% of the outstanding number of shares of the Company’s common stock on the immediately preceding December 31, or (ii) 490,336 shares.
	Restricted Stock
	Upon inception of the Company in December 2012, 385,825 shares of common stock were issued for $980. Of these shares, 196,849 were issued to 5AM Ventures and the remaining 188,976 were issued to two of the Company’s founders. In February 2013, vesting restrictions were placed on 118,110 shares of the 188,976 shares issued to the two founders. Given there was no change in fair value of the common stock, the modification of the founders’ stock agreements did not result in any incremental expense on the date of modification. The shares purchased by 5AM Ventures contained no vesting provisions.
	The Company did not issue any shares of common stock to employees or consultants during the three months ended March 31, 2015.  During the three months ended March 31, 2014, 75,860 shares of common stock were issued to employees and consultants of the Company at a price of $0.13 per share.
	Except for the shares purchased by 5AM Ventures, all shares issued since inception were subject to service-based vesting terms and the vesting of certain shares will accelerate on changes of control or termination of employment. At March 31, 2015, 242,273 shares were vested and 29,054 shares were subject to repurchase by the Company. At December 31, 2014, 231,669 were vested and 39,686 shares were subject to repurchase by the Company.
	Stock Options
	During the three months ended March 31, 2015, options to purchase 755,291 shares of common stock were granted to employees and non-employees. No options to purchase shares of common stock were granted during the three months ended March 31, 2014.
	The following table summarizes stock option activity during the three months ended March 31, 2015:
		Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Total Aggregate Intrinsic Value
	Outstanding at December 31, 2014		709,136		$	2.29		9.73	$	2,522
	Options granted		755,291			7.37
	Options exercised		(47,648	)		2.44
	Outstanding at March 31, 2015		1,416,779			4.99		9.71		14,199
	Vested and expected to vest at March 31, 2015		1,416,779			4.99		9.71		14,199
	Vested at March 31, 2015		41,067			4.39		9.67		436
	Exercisable at March 31, 2015		1,209,806		$	5		9.72	$	12,113
	The Company’s stock option plan allows for the early exercise of awards subject to the right of repurchase by the Company at the lower of original exercise price or fair market value for unvested awards. At March 31, 2015, the Company recorded a liability for the cash received from the early exercise of stock options in the amount of $840,000 which is classified in accrued liabilities on the balance sheet. The Company reduces the liability as the underlying shares vest in accordance with the vesting terms outlined in the stock option agreements which, generally, is 4 years. At March 31, 2015, 365,982 shares of common stock were issued as a result of exercises of stock options that were unvested.
	Stock-based compensation expense recognized for restricted shares and stock options granted to employees and consultants has been reported in the statements of operations as follows (in thousands):
		Three months ended
		March 31,
		2015			2014
	Research and development	$	442		$	2
	General and administrative		197			-
	Total	$	639		$	2
	The weighted-average grant date fair value of stock options granted by the Company during the three months ended March 31, 2015 was $7.37 per share. The total grant date fair value of stock options that vested during the three months ended March 31, 2015 was $0.4 million. As of March 31, 2015, total unrecognized share-based compensation costs related to unvested employee stock options of the Company were approximately $4.9 million. This unrecognized cost is expected to be recognized over a weighted-average period of approximately 2.9 years on a straight-line basis.
	Common stock reserved for issuance is as follows:
		31-Mar-15			31-Dec-14
	Conversion of Series A preferred		3,839,604			3,839,604
	Conversion of Series B preferred		3,721,776			-
	Stock options issued and outstanding		1,416,779			709,136
	Authorized for future stock awards or option grants		194,564			12,062
	Total		9,172,723			4,560,802

Purchase_of_Intellectual_Prope

Purchase of Intellectual Property from Seachaid Pharmaceuticals, Inc	3 Months Ended
	Mar. 31, 2015
Purchase Of Intellectual Property [Abstract]
Purchase of Intellectual Property from Seachaid Pharmaceuticals, Inc	7. PURCHASE OF INTELLECTUAL PROPERTY FROM SEACHAID PHARMACEUTICALS, INC.
	In May 2014, the Company entered into an asset purchase agreement with Seachaid Pharmaceuticals, Inc., or Seachaid, whereby the Company purchased intellectual property related to its antifungal product candidates, CD101 IV and CD101 topical. The Company issued 703,092 shares of common stock to Seachaid, with an estimated fair value of $1.6 million, as consideration for the assets acquired.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. COMMITMENTS AND CONTINGENCIES
	Litigation—From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are no claims or actions pending against the Company as of March 31, 2015 or 2014 which will have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm the Company’s business.
	Lease Obligations—In June 2014, the Company entered into an operating lease agreement for laboratory and office space in San Diego, California. Amendments for additional space were entered into in February and March 2014.  The lease expires in July 2016 with two individual two-year extension option rights. The lease is subject to charges for common area maintenance and other costs. Rent expense is being recorded on a straight-line basis over the life of the lease. Future minimum payments required under the lease as of March 31, 2015 are summarized as follows (in thousands):
	2015 (Three quarters remaining)	$	347
	2016		253
	Total minimum lease payments	$	600
	The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on or within 30 days of notice.
	The Company did not occupy any facilities prior to establishing itself in San Diego in July 2014. Rent expense was $104,000 and $0 for the three months ended March 31, 2015 and 2014, respectively.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	9. SUBSEQUENT EVENTS
	Reverse Stock Split
	On April 2, 2015, the Company’s board of directors and stockholders approved a 1-for-25.4 reverse stock split of its outstanding common stock. The reverse stock split resulted in an adjustment to the conversion prices of the Series A preferred and Series B preferred to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion, which occurred in connection with the closing of the Company’s IPO.  The accompanying financial statements and notes to the financial statements give retroactive effect to the reverse stock split for all periods presented.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Description of Business	Description of Business
	Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives. The Company’s initial product portfolio is comprised of proprietary product candidates for the treatment of serious fungal infections.
Initial Public Offering	Initial Public Offering
	On April 20, 2015, the Company completed its initial public offering (“IPO”) whereby the Company sold 4,800,000 shares of common stock at a price of $16.00 per share.  Proceeds from the IPO were approximately $69.4 million, net of underwriting discounts and commissions and offering costs.  In connection with the IPO, the outstanding shares of the Company’s Series A convertible preferred stock (“Series A preferred”) and Series B convertible preferred stock (“Series B preferred”) automatically converted into 7,561,380 shares of common stock.
Basic of Presentation	Basis of Presentation
	The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced net losses and negative cash flows from operating activities since its inception. At March 31, 2015, the Company had an accumulated deficit of $20.0 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. The Company plans to continue to fund its losses from operations and capital funding needs through debt and equity financing or through collaborations or partnerships with other companies. Debt or equity financing may not be available on a timely basis on terms acceptable to the Company, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects.
Use of Estimates	Use of Estimates—The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company’s financial statements relate to estimating the fair value of the Company’s common shares used to account for share-based compensation, accounting for certain accruals and the fair value of the Company’s convertible notes payable. Although the estimates are based on the Company’s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
Segment Information	Segment Information—Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.
Comprehensive Loss	Comprehensive Loss—Net loss and comprehensive loss were the same for all periods presented; therefore, a separate statement of comprehensive loss is not included in the accompanying financial statements.
Cash and Cash Equivalents	Cash and Cash Equivalents—The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents. At times, the Company has cash and cash equivalents deposited at financial institutions in excess of federally insured deposit limits. However, cash is held on deposit in major financial institutions and is considered subject to minimal credit risk. Cash and cash equivalents are readily available in checking and money market accounts.
Fair Value of Financial Instruments	Fair Value of Financial Instruments—Financial instruments including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate their fair value based on the short maturities of those instruments.
Concentration of Credit Risk	Concentration of Credit Risk—The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. Periodically, the Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.
Deferred Initial Public Offering Costs	Deferred Initial Public Offering Costs—As of March 31, 2015, the Company had capitalized approximately $1.5 million of costs directly associated with the Company’s IPO. The Company will offset deferred IPO costs against IPO proceeds upon the consummation of the offering. Deferred IPO costs are included as a component of other long-term assets on the balance sheet.
Patent Costs	Patent Costs—The legal and professional costs incurred by the Company to acquire patent rights have been recorded as general and administrative expense since recoverability of such expenditures is uncertain.
Convertible Preferred Stock	Convertible Preferred Stock—The Company’s Series A preferred and Series B preferred are classified as temporary equity instead of stockholders’ deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities, as the stock is conditionally redeemable at the holder’s option and upon certain change in control events that are outside the Company’s control, including the liquidation, sale, or transfer of control of the Company. Upon such change in control events, holders of the convertible preferred stock can cause its redemption.
Income Taxes	Income Taxes—The Company follows the FASB Accounting Standards Codification, or ASC, 740 Income Taxes, or ASC 740, in reporting deferred income taxes. The ASC 740 requires a company to recognize deferred tax liabilities and assets for expected future income tax consequences of events that have been recognized in the Company’s financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.
Research and Development Costs	Research and Development Costs—To date, research and development expenses have related primarily to research and preclinical development of CD101 IV, CD101 topical, and the Cloudbreak immunotherapy platform. Research and development expenses include compensation and benefits for research and development employees, and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.
	Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.
Stock-based Compensation	Stock-based Compensation—Stock-based compensation expense represents the cost of the grant date fair value of employee stock option and restricted stock grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. The Company accounts for stock options granted to non-employees using the fair value approach. These option grants are subject to periodic revaluation over their vesting terms. The Company estimates the fair value of employee and non-employee stock option grants using the Black-Scholes option pricing model, or Black-Scholes.
Net Loss Per Share	Net Loss Per Share—Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, convertible notes payable, unvested restricted common stock subject to repurchase, and options outstanding under the Company’s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.
	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):
		Three months ended
		March 31,
		2015		2014
	Convertible preferred stock		7,561,380		-
	Common stock options		1,416,779		-
	Common stock subject to repurchase		395,087		56,822
	Total		9,373,246		56,822
Fair Value of Financial Instruments	Fair Value of Financial Instruments—The Company follows authoritative guidance with respect to fair value reporting issued by the FASB for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.
Recently Issued Accounting Standards	Recently Issued Accounting Standards—The Company has evaluated the recent accounting pronouncements through the date of this filing, and management does not expect adoption of such pronouncements to have a material impact on the Company’s financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive (in common stock equivalent shares):
		Three months ended
		March 31,
		2015		2014
	Convertible preferred stock		7,561,380		-
	Common stock options		1,416,779		-
	Common stock subject to repurchase		395,087		56,822
	Total		9,373,246		56,822

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured at Fair Value on Recurring Basis	The following tables summarize the Company’s financial instruments measured at fair value on a recurring basis:
				LEVEL 1		LEVEL 2		LEVEL 3
		TOTAL		QUOTED		SIGNIFICANT		SIGNIFNCANT
				PRICES IN		OTHER		UNOBSERVABLE
				ACTIVE		OBSERVABLE		INPUTS
				MARKETS		INPUTS
				FOR IDENTICAL
				SECURITIES
	31-Dec-14
	Assets:
	Money market funds, included in cash and cash equivalents	$	20,769	$	20,769	$	-	$	-
	Total assets at fair value	$	20,769	$	20,769	$	-	$	-
	31-Mar-15
	Assets:
	Money market funds, included in cash and cash equivalents	$	56,372	$	56,372	$	-	$	-
	Total assets at fair value	$	56,372	$	56,372	$	-	$	-

Stock_Incentive_Plan_Tables

Stock Incentive Plan (Tables)	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Schedule of Stock Option Activity	The following table summarizes stock option activity during the three months ended March 31, 2015:
		Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Total Aggregate Intrinsic Value
	Outstanding at December 31, 2014		709,136		$	2.29		9.73	$	2,522
	Options granted		755,291			7.37
	Options exercised		(47,648	)		2.44
	Outstanding at March 31, 2015		1,416,779			4.99		9.71		14,199
	Vested and expected to vest at March 31, 2015		1,416,779			4.99		9.71		14,199
	Vested at March 31, 2015		41,067			4.39		9.67		436
	Exercisable at March 31, 2015		1,209,806		$	5		9.72	$	12,113
Summary of Stock-based compensation expense recognized for restricted shares and stock options granted to employees and consultants	Stock-based compensation expense recognized for restricted shares and stock options granted to employees and consultants has been reported in the statements of operations as follows (in thousands):
		Three months ended
		March 31,
		2015			2014
	Research and development	$	442		$	2
	General and administrative		197			-
	Total	$	639		$	2
Summary of common stock reserved for issuance	Common stock reserved for issuance is as follows:
		31-Mar-15			31-Dec-14
	Conversion of Series A preferred		3,839,604			3,839,604
	Conversion of Series B preferred		3,721,776			-
	Stock options issued and outstanding		1,416,779			709,136
	Authorized for future stock awards or option grants		194,564			12,062
	Total		9,172,723			4,560,802

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum payments required under the lease as of March 31, 2015 are summarized as follows (in thousands):
	2015 (Three quarters remaining)	$	347
	2016		253
	Total minimum lease payments	$	600

The_Company_and_Basis_of_Prese1

The Company and Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended	0 Months Ended
	Mar. 31, 2015	Apr. 20, 2015	Dec. 31, 2014
	Segment
Business Description And Basis Of Presentation [Line Items]
Common stock, shares issued	1,542,155		1,494,506
Accumulated deficit	($20,041,000)		($13,304,000)
Number of Operating Segments	1
Common Stock | Subsequent Events
Business Description And Basis Of Presentation [Line Items]
Convertible preferred stock in to shares of common stock		7,561,380
Initial Public Offering | Subsequent Events
Business Description And Basis Of Presentation [Line Items]
Common stock, shares issued		4,800,000
Sale of common stock, price per share		$16
Net proceeds from sale of common stock		$69,400,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Details) (USD $)	Mar. 31, 2015
In Millions, unless otherwise specified
Accounting Policies [Abstract]
Capitalized cost associated with initial public offering	$1.50

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded in the calculation of diluted net loss per share	9,373,246	56,822
Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded in the calculation of diluted net loss per share	7,561,380
Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded in the calculation of diluted net loss per share	1,416,779
Common Stock Subject to Repurchase
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded in the calculation of diluted net loss per share	395,087	56,822

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Details) (Fair Value, Measurements, Nonrecurring, USD $)	Mar. 31, 2015
Fair Value, Measurements, Nonrecurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of assets	$0
Fair value of liabilities	$0

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) (Fair Value Measurements Recurring Basis, USD $)	Mar. 31, 2015	Dec. 31, 2014
Assets:
Total assets at fair value	$56,372	$20,769
Money Market Funds Included in Cash and Cash Equivalents
Assets:
Total assets at fair value	56,372	20,769
Level 1
Assets:
Total assets at fair value	56,372	20,769
Level 1 | Money Market Funds Included in Cash and Cash Equivalents
Assets:
Total assets at fair value	$56,372	$20,769

Debt_Additional_Information_De

Debt - Additional Information (Details) (USD $)	3 Months Ended		1 Months Ended	2 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2013	Feb. 28, 2014	30-May-14	Jan. 31, 2014
Debt Instrument [Line Items]
Amortization of debt issue costs	$6,000	$10,000
Comerica Loan [Member]
Debt Instrument [Line Items]
Warrant purchase price	$8.53
Warrant expiration date	29-Dec-15
Costs incurred in execution of loan	22,000
Comerica Loan [Member] | Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Borrowing capacity	10,000,000
Line of credit facility, term	12 months
Number of installments	36
Loan due date	31-Dec-18
Series A Convertible Preferred Stock | Comerica Loan [Member] | Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Warrants issued to purchase preferred stock	1.50%
2013 Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible notes issued			1,250,000
Interest rate			8.00%
Conversion discount rate			15.00%
Proceeds from sale of equity securities			13,750,000
Notes maturity date	8-Feb-14
Notes extended maturity date	30-Jul-14
2014 Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible notes issued				$450,000		$500,000
Interest rate				8.00%
Conversion discount rate				15.00%
Notes maturity date	30-Jul-14
2014 Convertible Notes Payable [Member] | Series A Convertible Preferred Stock
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued					321,492

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Details) (USD $)	3 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Feb. 28, 2015	Dec. 31, 2014
Class Of Stock [Line Items]
Proceeds from sales of Series B convertible preferred stock, gross issuance costs	$41,921
Series A and Series B Convertible Preferred Stock
Class Of Stock [Line Items]
Minimum percentage of votes required for conversion of preferred stock	60.00%
Convertible preferred stock, terms of conversion	Each share of Preferred is optionally convertible at any time at the discretion of the holder. All shares of Preferred are convertible upon the election of the holders of at least 60% of the Preferred.
Convertible preferred stock, settlement terms	In the event of an IPO at an effective price per common share greater than three times the Original Issue Price, the Preferred will automatically convert into common stock, and all declared and unpaid dividends on the Series A preferred shall be paid.
Preferred stock, dividend rate percentage	8.00%
Preferred stock, dividend payment terms	Dividends will be paid only on declaration by the board of directors and shall be non-cumulative.
Preferred stock, dividend preference	If dividends are paid on shares of common stock, the holders of Preferred will receive an additional dividend equal to the amount paid or set aside for each share of common stock, on an as-if-converted to common stock basis.
Series A Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, shares authorized	97,972,510		127,214,000
Convertible preferred stock, shares issued	97,526,081		97,526,081
Series B Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, shares authorized	94,600,000		0
Convertible preferred stock, shares issued	94,533,183	94,533,183	0
Proceeds from sales of Series B convertible preferred stock, gross issuance costs		$42,000
Preferred stock, original issue price	$0.44

Stock_Incentive_Plan_Additiona

Stock Incentive Plan - Additional Information (Details) (USD $)	3 Months Ended	12 Months Ended	1 Months Ended	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Feb. 28, 2013	Mar. 31, 2014	Dec. 31, 2012	Apr. 14, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares authorized for issuance to employees, nonemployee directors, and consultants	194,564	12,062
Common stock reserved for issuance	9,172,723	4,560,802
Common stock, shares issued	1,542,155	1,494,506
Common stock value issued	$3,000	3,000
Vested shares	41,067
Number of stock options, granted	755,291
Weighted average grant date fair values of stock options granted	$7.37
Grant date fair value of stock options, vested	400,000
Unrecognized share-based compensation costs of unvested employee stock options	4,900,000
Recognized weighted average period	2 years 10 months 24 days
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity incentive plan effective date	14-Apr-15
Equity incentive plan, description	In addition, the number of shares of stock available for issuance under the ESPP will be automatically increased each January 1, beginning on January 1, 2016, by the lesser of (i) 1% of the outstanding number of shares of the Companybs common stock on the immediately preceding December 31, or (ii) 490,336 shares.
Automatic annual increase in shares authorized for issuance in equity incentive plan	1.00%
Common stock shares outstanding	490,336
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued					385,825
Common stock value issued					980
Vested shares	242,273	231,669
Shares subject to repurchase	29,054	39,686
Restricted Stock | Employees and consultants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued	0			75,860
Common stock shares issued, price per share				0.13
Restricted Stock | 5AM Ventures
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued					196,849
Restricted Stock | Founders
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares issued					188,976
Vested shares			118,110
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vesting period	4 years
Common stock, shares issued	365,982
Number of stock options, granted	755,291			0
Cash received on stock options	$840,000
Subsequent Events | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance						245,168
2013 Option and Grant Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vesting period	4 years
Stock options grant period from date of grant	10 years
Price of stock option as percentage of estimated fair value of shares on date of grant	100.00%
Shares authorized for issuance to employees, nonemployee directors, and consultants	2,064,624	1,126,813
Shares available for future grants or awards	194,564
2013 Option and Grant Plan | More than 10% of voting power
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Price of stock option as percentage of estimated fair value of shares on date of grant	110.00%
2015 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity incentive plan effective date	14-Apr-15
Common stock reserved for issuance	1,634,456
Equity incentive plan, description	The number of shares reserved that are remaining under the 2013 Plan will be added to the shares initially reserved under the 2015 Plan upon its effectiveness. In addition, the number of shares of stock available for issuance under the 2015 Plan will be automatically increased each January 1, beginning on January 1, 2016, by 4% of the outstanding number of shares of the Companybs common stock on the immediately preceding December 31 or such lesser number as determined by the Companybs board of directors
Automatic annual increase in shares authorized for issuance in equity incentive plan	4.00%

Stock_Incentive_Plan_Summary_o

Stock Incentive Plan - Summary of Stock Option Activity (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares, Outstanding, beginning balance	709,136
Number of stock options, granted	755,291
Number of Shares, Options exercised	-47,648
Number of Shares, Outstanding ending balance	1,416,779	709,136
Number of Shares, Vested and expected to vest	1,416,779
Number of Shares, Vested	41,067
Number of Shares, Exercisable	1,209,806
Weighted Average Exercise Price, Outstanding, beginning balance	$2.29
Weighted Average Exercise Price, Options granted	$7.37
Weighted Average Exercise Price, Options exercised	$2.44
Weighted Average Exercise Price, Outstanding, ending balance	$4.99	$2.29
Weighted Average Exercise Price, Vested and expected to vest	$4.99
Weighted Average Exercise Price, Vested	$4.39
Weighted Average Exercise Price, Exercisable	$5
Weighted Average Remaining Contractual Life in Years, Vested and expected to vest	9 years 8 months 16 days	9 years 8 months 23 days
Weighted Average Remaining Contractual Life in Years, Outstanding	9 years 8 months 16 days
Weighted Average Remaining Contractual Life in Years, Vested and expected to vest	9 years 8 months 16 days	9 years 8 months 23 days
Weighted Average Remaining Contractual Life in Years, Vested	9 years 8 months 1 day
Weighted Average Remaining Contractual Life in Years, Exercisable	9 years 8 months 19 days
Outstanding at December 31, 2014	$2,522
Total Aggregate Intrinsic Value, Outstanding at March 31, 2015	14,199	2,522
Total Aggregate Intrinsic Value, Vested and expected to vest	14,199
Total Aggregate Intrinsic Value, Vested	436
Total Aggregate Intrinsic Value, Exercisable	$12,113

Stock_Incentive_Plan_Summary_o1

Stock Incentive Plan - Summary of Stock-Based Compensation Expense Recognized for Restricted Shares and Stock Options Granted to Employees and Consultants (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$639	$2
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	442	2
General and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$197

Recovered_Sheet1

Stock incentive plan - Summary of common stock reserved for issuance (Detail)	Mar. 31, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance	9,172,723	4,560,802
Stock options issued and outstanding	1,416,779	709,136
Shares authorized for issuance to employees, nonemployee directors, and consultants	194,564	12,062
Conversion of Series A preferred
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance	3,839,604	3,839,604
Conversion of Series B preferred
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance	3,721,776

Purchase_of_Intellectual_Prope1

Purchase of Intellectual Property from Seachaid Pharmaceuticals, Inc - Additional Information (Details) (USD $)	1 Months Ended
In Millions, except Share data, unless otherwise specified	31-May-14
Purchase Of Intellectual Property [Abstract]
Common stock shares issued for consideration of assets acquired	703,092
Fair value of assets acquired in purchase agreement	$1.60

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
	OptionRights	Claims
	Claims
Commitments And Contingencies Disclosure [Abstract]
Number of claims and actions pending	0	0
Description of lease arrangements, operating leases	The lease expires in July 2016 with two individual two-year extension option rights.
Number Of operating lease extension option rights	2
Operating lease expiration date	31-Jul-16
Operating leases renewal term per extension option rights	2 years
Operating lease contract termination notice period	30 days
Lease rent expense	$104,000	$0

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Lease Payment (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Operating Leases Future Minimum Payments Due [Abstract]
2015 (Three quarters remaining)	$347
2016	253
Total minimum lease payments	$600

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Details) (Subsequent Events)	0 Months Ended
	Apr. 02, 2015
Subsequent Events
Subsequent Event [Line Items]
Reverse split of common stock	Companybs board of directors and stockholders approved a 1-for-25.4 reverse stock split
Reverse stock split ratio	0.03937